CMTA is leading a coordinated CMT1A research strategy that connects disease models, drug development, biomarkers, delivery science, and clinical infrastructure to accelerate new treatments.
CMTA Funds Imaging Research on CMT2A’s Cellular Weakness
CMTA announced a $90,860 CMTA-STAR investment supporting advanced imaging research to examine how MFN2 mutations disrupt cellular transport in CMT2A.
Tiny Movers, Big Clues: Dr. Manor Uses AI to Study CMT2A
CMTA-funded CMT2A treatment research at UC San Diego is building the tools to develop ASO therapies targeting the faulty MFN2 gene, with a clear path toward treatments.
CMTA’s Commitment to The Inherited Neuropathy Consortium
CMTA strengthens its role as the leading force in comprehensive CMT research, forging a strategic...
